dendritic cell based psma immunotherapy for prostate cancer using a cd40-targeted adenovirus vector基于树突状细胞免疫疗法对前列腺癌psma使用cd40-targeted腺病毒载体.pdfVIP

Dendritic Cell Based PSMA Immunotherapy for Prostate Cancer Using a CD40-Targeted Adenovirus Vector 1 1 1 1 1 1 Briana Jill Williams , Shilpa Bhatia , Lisa K. Adams , Susan Boling , Jennifer L. Carroll , Xiao-Lin Li , 1 2 2 3 4 Donna L. Rogers , Nikolay Korokhov , Imre Kovesdi , Alexander V. Pereboev , David T. Curiel , J. Michael Mathis1* 1 Gene Therapy Program, Departments of Urology, Biochemistry and Molecular Biology, and Cellular Biology and Anatomy, and the Feist-Weiller Cancer Center, LSU Health Sciences Center, Shreveport, Louisiana, United States of America, 2 VectorLogics, Inc., Birmingham, Alabama, United States of America, 3 Departments of Medicine and Pathology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 4 Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America Abstract Human prostate tumor vaccine and gene therapy trials using ex vivo methods to prime dendritic cells (DCs) with prostate specific membrane antigen (PSMA) have been somewhat successful, but to date the lengthy ex vivo manipulation of DCs has limited the widespread clinical utility of this approach. Our goal was to improve upon cancer vaccination with tumor antigens by delivering PSMA via a CD40-targeted adenovirus vector directly to DCs as an efficient means for activation and antigen presentation to T-cells. To test this approach, we developed a mouse model of prostate cancer by generating clonal derivatives of the mouse RM-1 p